Sam Brusco, Associate Editor08.30.23
Non-profit pediatric initiative CobiCure MedTech has granted $2 million in funding to PolyVascular, a Houston, Texas company developing a first-of-its-kind, non-surgical heart valve for young children with congenital heart disease.
CobiCure MedTech’s resource and funding grant bolsters the $3.5 million in grants previously secured from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase I and Phase II, as well as $750,000 from private funding.
CobiCure MedTech said its strategic support, resources, and funding will be used to further advance development of PolyVascular’s novel, polymer heart valve through clinical readiness. According to the Centers for Disease Control, congenital heart defects affect almost 40,000 births annually.
The company also said its mission is to combat the lack of investment for pediatrics that limits the number of approved pediatric medical devices.
"CobiCure's mission, strategic ecosystem, and critical resources are a perfect match for helping PolyVascular realize their goal of eliminating invasive surgeries in children with congenital heart disease," Emma Moran, Ph.D., Director of Strategy & Development at CobiCure MedTech, told the press. "Our commitment to supporting life-changing medical devices like PolyVascular's will fill gaps in pediatric MedTech and we look forward to the positive impact it could have on children's lives."
"This investment from CobiCure MedTech is a testament to the progress our team has made and acknowledges the need for better solutions for children with congenital heart disease," added PolyVascular founder and pediatric cardiologist, Henri Justino, MD. "We're grateful for the trust placed in our team by CobiCure. With their support, we are one step closer to reaching this vulnerable population to improve their quality of life and offer parents greater peace of mind."
CobiCure MedTech’s resource and funding grant bolsters the $3.5 million in grants previously secured from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase I and Phase II, as well as $750,000 from private funding.
CobiCure MedTech said its strategic support, resources, and funding will be used to further advance development of PolyVascular’s novel, polymer heart valve through clinical readiness. According to the Centers for Disease Control, congenital heart defects affect almost 40,000 births annually.
The company also said its mission is to combat the lack of investment for pediatrics that limits the number of approved pediatric medical devices.
"CobiCure's mission, strategic ecosystem, and critical resources are a perfect match for helping PolyVascular realize their goal of eliminating invasive surgeries in children with congenital heart disease," Emma Moran, Ph.D., Director of Strategy & Development at CobiCure MedTech, told the press. "Our commitment to supporting life-changing medical devices like PolyVascular's will fill gaps in pediatric MedTech and we look forward to the positive impact it could have on children's lives."
"This investment from CobiCure MedTech is a testament to the progress our team has made and acknowledges the need for better solutions for children with congenital heart disease," added PolyVascular founder and pediatric cardiologist, Henri Justino, MD. "We're grateful for the trust placed in our team by CobiCure. With their support, we are one step closer to reaching this vulnerable population to improve their quality of life and offer parents greater peace of mind."
